Formulation and characterization of Paclitaxel, 5-FU and Paclitaxel+5-FU microspheres

被引:56
作者
Gupte, A [1 ]
Ciftci, K [1 ]
机构
[1] Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19140 USA
关键词
microspheres; poly(lactide-co-glycolide); Paclitaxel; 5-flourouracil;
D O I
10.1016/j.ijpharm.2004.02.023
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The purpose of this study was to compare the combination (Paclitaxel +5-FU microspheres) with a single drug chemotherapy (Paclitaxel and 5-FU microspheres) against metastatic breast cancer cell line (MDA-MB 435 S). The physicochemical characteristics of the microspheres (i.e. encapsulation efficiency, particle size distribution, in vitro release, thermal characteristics) were studied. The results demonstrated that the encapsulation efficiency of Paclitaxel was high (90%) when the drug was encapsulated in poly(lactic-co-glycolic acid) (PLGA) microparticles with or without 5-fluorouracil (5-FU). However, the encapsulation efficiency of 5-FU was low (19%) and increased to 30% when the drug was encapsulated with Paclitaxel. The mean particle size of microspheres was 2.5 mum and were spherical in shape. The in vitro release of both 5-FU and Paclitaxel from the microspheres was relatively fast initially followed by a slower and more controlled release. The cytotoxic activity of Paclitaxel microspheres was far greater compared to either the microspheres containing 5-FU + Paclitaxel or 5-FU alone. Overall results demonstrated that incorporation of Paclitaxel or 5-FU in microspheres enhances the cytotoxicity in more controlled manner compared to that of free drugs and also that careful consideration should be made when combining drugs acting in different phases of cell cycle. (C) 2004 Elsevier B.V All rights reserved.
引用
收藏
页码:93 / 106
页数:14
相关论文
共 27 条
[1]
PREPARATION AND CHARACTERIZATION OF MICROOSPHERES CONTAINING THE ANTI-INFLAMMATORY AGENTS, INDOMETHACIN, IBUPROFEN, AND KETOPROFEN [J].
BODMEIER, R ;
CHEN, H .
JOURNAL OF CONTROLLED RELEASE, 1989, 10 (02) :167-175
[2]
In vitro and in vivo evaluation of an ocular delivery system of 5-fluorouracil microspheres [J].
Chiang, CH ;
Tung, SM ;
Lu, DW ;
Yeh, MK .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2001, 17 (06) :545-553
[3]
In vitro and in vivo evaluation of PLAGA (50/50) microspheres containing 5-fluorouracil prepared by a solvent evaporation method [J].
Ciftci, K ;
Kas, HS ;
Hincal, AA ;
Ercan, TM ;
Guven, O ;
Ruacan, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 131 (01) :73-82
[4]
TAXOL ENCAPSULATION IN POLY(EPSILON-CAPROLACTONE) MICROSPHERES [J].
DORDUNOO, SK ;
JACKSON, JK ;
ARSENAULT, LA ;
OKTABA, AMC ;
HUNTER, WL ;
BURT, HM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 36 (04) :279-282
[5]
THERMOANALYSIS OF MICROSPHERES [J].
DUBERNET, C .
THERMOCHIMICA ACTA, 1995, 248 :259-269
[6]
Fan WM, 1998, ONCOL REP, V5, P1035
[7]
Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymers [J].
Feng, SS ;
Huang, GF .
JOURNAL OF CONTROLLED RELEASE, 2001, 71 (01) :53-69
[8]
Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity [J].
Fonseca, C ;
Simoes, S ;
Gaspar, R .
JOURNAL OF CONTROLLED RELEASE, 2002, 83 (02) :273-286
[9]
Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells [J].
Grem, JL ;
Nguyen, D ;
Monahan, BP ;
Kao, V ;
Geoffroy, FJ .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (03) :477-486
[10]
GREM JL, 1996, CANC CHEMOTHERAPY BI, P149